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The development of vaccines and therapeutics for COVID-19 requires a concerted global
commitment to share research.
Global research effort is usually highly competitive and undertaken by diverse parties. In the
COVID-19 context, this may result in discrepancy between the amount of public funding available
and the cost of developing effective vaccines.
Intellectual property rights (particularly patents) on the technology behind vaccines can
encourage innovation and safeguard investment in research and development. However, they can
slow down development. Finding the right balance and coordinating a rapid response to this
pandemic is vital.
The COVID-19 pandemic has seen Australia, and other countries, committing promptly to
contributing toward a shared research and funding effort.
Among the many issues raised during the COVID-19 pandemic, there is increasing attention on how intellectual property rights,
particularly patents, are put into practice. For example, one of the conspiracy theories
(https://www.usatoday.com/story/news/factcheck/2020/03/27/covid-19-fact-check-bill-melinda-gates-foundation-did-not-patent-
coronavirus/2919503001/) currently in circulation claims that the novel coronavirus itself is patented, and therefore the patent
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holder will profit from any cure developed for the pandemic. This is by no means true. Yet issues involving intellectual property
rights, in all their guises, litter the COVID-19 landscape, and patents have the most significant potential to fuel discussion and
debate in the coronavirus response.
Patent rights exist everywhere around viral pandemics, as seen in simple Google searches for face masks
(https://patents.google.com/patent/US20080092909A1/en), ventilators (https://patents.google.com/patent/US6694978), therapies
(https://patents.google.com/patent/US9370578B2/en), diagnostics (https://patents.google.com/patent/US9470686B2/en), and
vaccines (https://patents.google.com/patent/US5948410A/en). Globally, many of these patents remain active, and many new
applications are being filed. A recent analysis identified hundreds of patents associated with SARS and MERS
(https://pubs.acs.org/doi/10.1021/acscentsci.0c00272) that, the authors claim, could be relevant in the COVID-19 context.
The rationale for patents is that they encourage innovation. By granting temporary time frames of exclusivity around uses of new
technologies, innovators are encouraged to embark on the process of commercial development. Yet questions abound: how new
must the technology be? How much exclusivity should be granted, and for how long? What is the extent of the advantage for
exclusivity? What uses might be allowed? And when might it be appropriate for governments to step in and take away or modify the
rights they have given?
These questions have been the subject of ongoing academic and policy debate for decades, but they are especially relevant now
during this global emergency.
Patents, pandemics and pursuit of vaccines
By law, there is potential for the Australian government to step in (https://corrs.com.au/insights/covid-19-when-do-private-patent-
rights-give-way-to-the-public-interest) and use patented technology ‘for the services of the state’, or to licence other providers to do
the same. Although our Patents Act 1990 allows such practices (https://blog.patentology.com.au/2020/03/why-it-is-unlikely-that-
australian.html), they are rarely, if ever, used. Government intervention is probably unnecessary for face masks and other forms of
personal protective equipment (PPE), but restrictions on the ability to repurpose patented therapeutics and to develop vaccines
raise more serious concerns.
Pharmaceutical companies have always guarded their patents (https://science.sciencemag.org/content/327/5969/1083) over new
chemical and biological medicines. Their rationale is that the high expense and risk of taking therapeutics through the regulatory
hurdles to prove they are safe, effective and useful means there needs to be a period of exclusivity (https://www.future-
science.com/doi/10.4155/fmc.09.138) once they are on the market. Difficulties will arise if patent holders refuse to permit
repurposing investigations to be undertaken by others. This is particularly concerning now, given that many of the patented
chemical or biological medicines for the treatment of viral infections such as SARS, MERS, influenza, HCV, and Ebola may be
suitable for repurposing (https://pubs.acs.org/doi/10.1021/acscentsci.0c00272).
However, some of the major patent holders are taking the pragmatic approach of temporarily suspending enforcement of their
patent rights (https://www.natlawreview.com/article/covid-19-update-patent-rights-covid-19-pandemic-how-will-industries-and-
governments) for the duration of the pandemic. In some countries, such as Germany (https://fortune.com/2020/04/02/coronavirus-
crisis-suspension-drug-patents/), Israel (https://www.who.int/news-room/detail/13-03-2020-who-un-foundation-and-partners-
launch-first-of-its-kind-covid-19-solidarity-response-fund), Chile (https://www.statnews.com/pharmalot/2020/03/18/chile-
compulsory-licensing-coronavirus-covid19-vaccines/) and Canada (https://www.parl.ca/DocumentViewer/en/43-1/bill/C-13/royal-
assent), governments are taking pre-emptive steps (http://www.kwm.com/en/au/knowledge/insights/patent-rights-during-covid-19-
can-the-government-step-in-20200403) to ensure that uses for COVID-19 purposes remain open. A group of scientists and
organisations have pledged to make their intellectual property free of charge for use in COVID-19 research
(https://opencovidpledge.org/). Not all patent holders are taking this benevolent approach and organisations such as Médecins
Sans Frontières (https://www.msf.org/no-profiteering-covid-19-drugs-and-vaccines-says-msf) (Doctors Without Borders) are calling
for others to do the same.
With vaccine development, the need to act quickly, and the consequences of not doing so, could be significant. Although there is no
evidence yet that patents are being used in ways that might delay COVID-19 vaccine development in Australia, we should not be
complacent. The World Health Organization (WHO) has prioritised the accelerated development of vaccines
(https://www.who.int/news-room/detail/12-02-2020-world-experts-and-funders-set-priorities-for-covid-19-research) and established
the COVID-19 Solidarity Response Fund (https://covid19responsefund.org/), which will rely partly on philanthropic and public
funding. It is estimated that the cost of developing a COVID-19 vaccine is in the vicinity of US$2 billion (https://wellcome.ac.uk/what-
we-do/our-work/coronavirus-covid-19/investment). To contribute to the global effort of developing a COVID-19 vaccine, the World
Bank and the Coalition for Epidemic Preparedness Innovations (CEPI) recently launched a COVID-19 Vaccine Development
Taskforce, which the University of Queensland (https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine)
was invited to join.
Globally we are seeing huge research efforts being poured into COVID-19 treatments and vaccine research. The number of articles
related to COVID-19 (http://covid19primer.com/dashboard) published in scientific journals has steadily increased since the outbreak
of the virus, with many of these proving to be highly influential in the quest for a vaccine. WHO promotes sharing of research data
(https://www.who.int/bulletin/volumes/98/3/20-251561/en/) to ensure vaccine development remains in the public sphere. Patent
ownership of rights to vaccine development and distribution would conflict with this and other public initiatives.
Many of the patented chemical or biological medicines for the treatment of viral infections such as SARS, MERS,
in uenza, HCV, and Ebola may be suitable for repurposing.
  As of 26 May 2020, 16,819 new published papers and preprints were released mentioning ‘covid-19 OR sars-cov-2 OR 2019-nCoV’. Courtesy of
Primer AI
 
Few specific COVID-19-related patent applications have been filed to date in Australia or anywhere else, but based on previous
vaccine races this seems inevitable. WHO and the World Intellectual Property Organisation report that large numbers of patent
rights have been fragmented across disparate parties (https://www.wipo.int/publications/en/details.jsp?id=264&plang=EN), each
seeking to claim rights (https://www.who.int/influenza/resources/Influenza_FullReport_01Apr2011.pdf) over the various components
that make up vaccines.
The current discrepancy between the amount of public funding available and the cost of developing effective vaccines highlights
the likelihood that private entities will become competitive players in the race for a vaccine and will subsequently seek to recoup
their investment. This push to patent is not surprising given the substantial investment required for development.
One consequence of patents is that competitors may be blocked from developing new vaccines using patented technologies.
Although it may be possible to negotiate licences to patents, this process will hinder the speed at which vaccine development can
occur. The question is how to overcome this incentivisation gulf during the current pandemic?
What can we learn from previous viral outbreaks?
To help understand which of the various options may work for COVID-19, we can learn from the approaches taken in previous viral
outbreaks. While WHO coordinated a concerted effort (https://www.who.int/mediacentre/news/notes/2003/np4/en/) to develop a
vaccine during the SARS outbreak, many of the parties involved filed patent applications. This led to a plan to ‘pool’ all patents
essential to SARS treatments or vaccines (https://research.vu.nl/en/publications/managing-severe-acute-respiratory-syndrome-
sars-intellectual-prop)—the idea being that users of the pool would be able to collectively license all patents essential to the
development of vaccines and treatments at a reasonable price. Early control of the outbreak meant the patent pool never
eventuated.
Other outbreaks have prompted similar initiatives. Unitaid (a global health initiative) and WHO initiated a patent pool to centralise a
number of essential patents relevant to HIV/AIDS treatment. This arrangement evolved into a pool containing many patents
(https://unitaid.org/project/medicines-patent-pool/#en) related to HIV, Hepatitis C and tuberculosis.
Setting up prize mechanisms (https://www.tandfonline.com/doi/abs/10.1080/19452829.2012.703172) to fund important prospective
scientific research is another solution that has been explored in the wake of public health crises. An alternative method is to promote
public–private partnerships that aim to encourage broad access to end products. This requires the agreement of patent holders not
to assert their patent rights against certain parties, including those in other countries.
Ultimately, effective vaccine development for COVID-19 depends on a concerted commitment to share research, clinical trials data
and virus samples (https://www.ncbi.nlm.nih.gov/pubmed/29048862). Supporting this, researchers are making their findings openly
available (https://www.science.org.au/curious/policy-features/open-science-after-covid-19-pandemic-there-can-be-no-return-
closed-working), which assists with the momentum of the united global response. This issue arose during the H5NI (bird flu) outbreak
(https://www.who.int/influenza/resources/documents/avian_flu_landscape.pdf?ua=1), when an Australian company patented an
H5NI vaccine (https://patents.google.com/patent/AU2004904356A0/en?oq=AU2004904356) derived from Indonesian samples
donated to the WHO Influenza Network. The Indonesian Government was then unable to access vaccine supplies
(http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.515.6610&rep=rep1&type=pdf) when the disease struck Indonesia. The
ensuing publicity resulted in the patent holder announcing it would license at no cost
(https://apps.who.int/iris/bitstream/handle/10665/69752/WHO_IVB_08.11_eng.pdf?sequence=1&isAllowed=y). The possibility that
the Australian Government might step in is also a likely incentive to voluntarily license.
The SARS pandemic aside, previous global efforts at developing vaccines have lacked the compelling urgency of the current COVID-
19 research push (https://www.sciencemag.org/news/2020/01/scientists-are-moving-record-speed-create-new-coronavirus-vaccines-
they-may-come-too). The severity of this pandemic, the likes of which the world has not seen for 100 years, has mobilised the global
research community (https://cepi.net/news_cepi/belgium-and-canada-provide-funding-boost-for-cepis-covid-19-vaccine-research/)
in the quest for a vaccine. Recently CSIRO was funded by CEPI (https://www.csiro.au/en/News/News-releases/2020/CSIRO-begins-
testing-Covid-19-vaccines) to test two promising vaccine candidates. The US Government has invested over US$400 million
(https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push)
(with additional industry support) to fund the development of promising vaccine candidates by two pharmaceutical companies.
Seasonal flu vaccines are generally incentivised through public funding in conjunction with WHO. However, the reality is that the
financial involvement of the private sector will be essential to complement public sector research to move COVID-19 vaccines rapidly
to the clinic.
The scale of the pandemic and vaccine requirements have the potential to change the landscape around the
patenting of vaccines.
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Although a pandemic of this scale was anticipated (https://www.nytimes.com/2020/02/27/opinion/coronavirus-pandemics.html), its
ferocity has shocked health authorities. The scale of the pandemic and vaccine requirements have the potential to change the
landscape around the patenting of vaccines. In line with broad principles of sharing
(https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30763-7.pdf), the Australian research effort should be guided by
the international effort and support and complement international research priorities. Australian Government commitment to assist
will help ensure equitable access to vaccines once developed: Australia, as other countries, must commit promptly to contributing
toward a shared research and funding effort (https://www.healthaffairs.org/do/10.1377/hblog20200326.869114/full/). The
government must also be prepared to use all of the regulatory tools available to it, should there be non-compliance with the spirit of
cooperation by individual entities. Private property rights have a limited place in global health crises of this nature.
This topic's links to the Sustainable Development Goals:
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